Iradimed (IRMD) AI Stock Analysis

• Market Cap: $1.29B
• Dividend Yield: 1.22%
• Average Volume (3M): 79.19K
• Price to Earnings (P/E): 61.5
• Beta (1Y): 0.68
• Revenue Growth: 12.91%
• EPS Growth: 13.24%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.47
• Shares Outstanding: 12,721,156
• 10 Day Avg. Volume: 84,424
• 30 Day Avg. Volume: 79,190
• PEG Ratio: 3.08
• Price to Book (P/B): 8.03
• Price to Sales (P/S): 9.51
• P/FCF Ratio: 39.55
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 10.66
• Enterprise Value/Gross Profit: 13.84
• Enterprise Value/Ebitda: 30.92
• 1Y Price Target: $99.00
• Price Target Upside: 29.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 2.1
• Revenue Forecast (FY): $90.22M

• Rating: 79 Outperform
• Price Target: $113.00 ▲(47.87% Upside)

IRMD scores well primarily due to strong financial performance (high margins, minimal leverage) and supportive technicals (clear uptrend with positive momentum). The elevated P/E meaningfully tempers the score, while the latest earnings call adds support via raised guidance and continued record revenue, partially offset by higher opex and international regulatory delays.

Positive Factors

Revenue Growth

Consistent revenue growth over 17 quarters indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Product Innovation

The introduction of innovative products like the 3870 MRI IV pump positions Iradimed as a leader in MRI-compatible technology, driving future growth.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability and provides flexibility for strategic investments and growth opportunities.

Negative Factors

High Operating Expenses

Rising operating expenses can pressure margins and reduce profitability, potentially impacting the company's ability to invest in growth initiatives.

Regulatory Challenges

Regulatory delays in key markets like Europe and Japan can hinder international expansion and limit revenue growth potential in these regions.

Limited International Sales Growth

Stagnant international sales suggest challenges in global market penetration, which could restrict overall revenue diversification and growth.

Iradimed Business Overview & Revenue Model

Company Description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

How the Company Makes Money

Iradimed generates revenue primarily through the sale of its MRI-compatible products, including infusion pumps and monitoring systems. The company has established a recurring revenue stream through the sale of disposables and accessories that are used in conjunction with its devices. Additionally, Iradimed benefits from strategic partnerships with healthcare providers and institutions, which facilitate the adoption of its technologies and expand its market reach. The company's revenue model is further supported by ongoing research and development efforts aimed at introducing new products and enhancing existing offerings, ultimately driving sales and market penetration.

Iradimed Financial Statement Overview

Summary

Iradimed demonstrates strong financial performance with robust revenue growth, high gross profit margins, and a healthy balance sheet with low debt. Cash flow is consistent, though capital expenditures have slightly impacted growth. There is room for improvement in net profit margins.

Income Statement

Iradimed has demonstrated robust revenue growth with a 41.0% increase from 2022 to 2023 and a further 14.0% increase in 2024. Gross profit margins have remained strong, averaging around 77% over recent periods. The company maintains healthy EBIT and EBITDA margins, showcasing strong operational efficiency and profitability. However, the net profit margin, while solid, indicates room for further optimization.

Balance Sheet

The balance sheet of Iradimed is very healthy, with a remarkably low debt-to-equity ratio, indicating minimal leverage risk. The equity ratio is strong, reflecting a robust balance of equity to total assets. ROE is impressive, showing efficient use of equity to generate profits. Overall, the company has a solid financial position with low liabilities relative to equity.

Cash Flow

Iradimed shows a positive cash flow trend, with stable free cash flow generation despite fluctuations in capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion from profits. The free cash flow to net income ratio is consistent, though recent capital expenditures have slightly impacted free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.51M	73.24M	65.56M	53.30M	41.81M	31.72M
Gross Profit	62.05M	56.35M	50.16M	41.28M	32.05M	23.57M
EBITDA	27.77M	22.78M	20.80M	16.30M	11.22M	582.73K
Net Income	21.18M	19.23M	17.19M	12.83M	9.33M	1.37M
Balance Sheet
Total Assets	114.72M	98.33M	92.16M	85.51M	82.88M	71.07M
Cash, Cash Equivalents and Short-Term Investments	56.53M	52.23M	49.76M	57.96M	62.50M	51.98M
Total Debt	0.00	154.69K	2.04M	2.21M	2.48M	2.72M
Total Liabilities	16.37M	11.51M	20.74M	11.84M	10.71M	9.68M
Stockholders Equity	98.35M	86.82M	71.42M	73.67M	72.17M	61.38M
Cash Flow
Free Cash Flow	14.30M	17.62M	5.46M	8.17M	10.52M	5.18M
Operating Cash Flow	25.01M	25.62M	13.47M	10.04M	11.26M	5.82M
Investing Cash Flow	-11.06M	-8.82M	-8.01M	-1.37M	648.24K	246.97K
Financing Cash Flow	-9.15M	-14.34M	-13.66M	-12.71M	24.43K	522.48K

Iradimed Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 76.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Positive. The current price of 76.42 is below the 20-day moving average (MA) of 97.95, below the 50-day MA of 93.14, and above the 200-day MA of 70.21, indicating a bullish trend. The MACD of 2.20 indicates Negative momentum. The RSI at 70.53 is Negative, neither overbought nor oversold. The STOCH value of 88.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRMD.

Iradimed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	79 Outperform	$1.29B	61.51	23.31%	1.22%	12.91%	13.24%
AXGN	66 Neutral	$1.42B	-637.14	-1.90%	―	18.72%	85.77%
BVS	64 Neutral	$640.59M	71.15	4.97%	―	1.58%	―
SIBN	57 Neutral	$756.74M	-34.40	-12.91%	―	23.27%	43.90%
OFIX	55 Neutral	$567.07M	-4.74	-24.60%	―	4.31%	3.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	45 Neutral	$975.99M	-1.96	-38.71%	―	4.99%	-7151.40%

Iradimed Corporate Events

Iradimed Declares Special Cash Dividend for Shareholders

On December 5, 2025, IRADIMED CORPORATION’s Board of Directors declared a special cash dividend of $0.50 per share, payable on December 30, 2025, to shareholders of record as of December 17, 2025. This decision reflects the company’s strong financial performance, including 17 consecutive quarters of record revenue, and its cash balance of $56.5 million, which exceeds operational needs. The dividend complements the company’s regular quarterly dividend program and highlights its commitment to maximizing shareholder returns.

The most recent analyst rating on (IRMD) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.